SHC Quote, Financials, Valuation and Earnings

ProPhase Labs, Inc. has a net margin of 15.55% compared to Sotera Health Co.'s net margin of -774.52%. Sotera Health Co.'s return on equity of 11.79% beat ProPhase Labs, Inc.'s return on equity of -90.24%.

Sotera Health Co. has a consensus price target of $18.93, signalling upside risk potential of 12.4%. On the other hand ProPhase Labs, Inc. has an analysts' consensus of $13.80 which suggests that it could grow by 10099.56%. Given that ProPhase Labs, Inc. has higher upside potential than Sotera Health Co., analysts believe ProPhase Labs, Inc. is more attractive than Sotera Health Co..

Sotera Health Co. has a beta of 1.815, which suggesting that the stock is 81.485% more volatile than S&P 500. In comparison ProPhase Labs, Inc. has a beta of -0.657, suggesting its less volatile than the S&P 500 by 165.684%.

Sotera Health Co. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProPhase Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sotera Health Co. pays -- of its earnings as a dividend. ProPhase Labs, Inc. pays out -- of its earnings as a dividend.

Sotera Health Co. quarterly revenues are $311.3M, which are larger than ProPhase Labs, Inc. quarterly revenues of $883K. Sotera Health Co.'s net income of $48.4M is higher than ProPhase Labs, Inc.'s net income of -$6.8M. Notably, Sotera Health Co.'s price-to-earnings ratio is 87.25x while ProPhase Labs, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sotera Health Co. is 4.18x versus 0.93x for ProPhase Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Thermo Fisher Scientific, Inc. has a net margin of 15.55% compared to Sotera Health Co.'s net margin of 14.58%. Sotera Health Co.'s return on equity of 11.79% beat Thermo Fisher Scientific, Inc.'s return on equity of 13.15%.

Sotera Health Co. has a consensus price target of $18.93, signalling upside risk potential of 12.4%. On the other hand Thermo Fisher Scientific, Inc. has an analysts' consensus of $619.96 which suggests that it could grow by 6.81%. Given that Sotera Health Co. has higher upside potential than Thermo Fisher Scientific, Inc., analysts believe Sotera Health Co. is more attractive than Thermo Fisher Scientific, Inc..

Sotera Health Co. has a beta of 1.815, which suggesting that the stock is 81.485% more volatile than S&P 500. In comparison Thermo Fisher Scientific, Inc. has a beta of 0.899, suggesting its less volatile than the S&P 500 by 10.144%.

Sotera Health Co. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Thermo Fisher Scientific, Inc. offers a yield of 0.29% to investors and pays a quarterly dividend of $0.43 per share. Sotera Health Co. pays -- of its earnings as a dividend. Thermo Fisher Scientific, Inc. pays out 9.43% of its earnings as a dividend. Thermo Fisher Scientific, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sotera Health Co. quarterly revenues are $311.3M, which are smaller than Thermo Fisher Scientific, Inc. quarterly revenues of $11.1B. Sotera Health Co.'s net income of $48.4M is lower than Thermo Fisher Scientific, Inc.'s net income of $1.6B. Notably, Sotera Health Co.'s price-to-earnings ratio is 87.25x while Thermo Fisher Scientific, Inc.'s PE ratio is 33.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sotera Health Co. is 4.18x versus 5.04x for Thermo Fisher Scientific, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Veracyte, Inc. has a net margin of 15.55% compared to Sotera Health Co.'s net margin of 14.51%. Sotera Health Co.'s return on equity of 11.79% beat Veracyte, Inc.'s return on equity of 2.52%.

Sotera Health Co. has a consensus price target of $18.93, signalling upside risk potential of 12.4%. On the other hand Veracyte, Inc. has an analysts' consensus of $47.10 which suggests that it could fall by -1.36%. Given that Sotera Health Co. has higher upside potential than Veracyte, Inc., analysts believe Sotera Health Co. is more attractive than Veracyte, Inc..

Sotera Health Co. has a beta of 1.815, which suggesting that the stock is 81.485% more volatile than S&P 500. In comparison Veracyte, Inc. has a beta of 1.829, suggesting its more volatile than the S&P 500 by 82.869%.

Sotera Health Co. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Veracyte, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sotera Health Co. pays -- of its earnings as a dividend. Veracyte, Inc. pays out -- of its earnings as a dividend.

Sotera Health Co. quarterly revenues are $311.3M, which are larger than Veracyte, Inc. quarterly revenues of $131.9M. Sotera Health Co.'s net income of $48.4M is higher than Veracyte, Inc.'s net income of $19.1M. Notably, Sotera Health Co.'s price-to-earnings ratio is 87.25x while Veracyte, Inc.'s PE ratio is 125.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sotera Health Co. is 4.18x versus 7.67x for Veracyte, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

XWELL, Inc. has a net margin of 15.55% compared to Sotera Health Co.'s net margin of -2.87%. Sotera Health Co.'s return on equity of 11.79% beat XWELL, Inc.'s return on equity of -224.93%.

Sotera Health Co. has a consensus price target of $18.93, signalling upside risk potential of 12.4%. On the other hand XWELL, Inc. has an analysts' consensus of -- which suggests that it could grow by 775%. Given that XWELL, Inc. has higher upside potential than Sotera Health Co., analysts believe XWELL, Inc. is more attractive than Sotera Health Co..

Sotera Health Co. has a beta of 1.815, which suggesting that the stock is 81.485% more volatile than S&P 500. In comparison XWELL, Inc. has a beta of 1.227, suggesting its more volatile than the S&P 500 by 22.697%.

Sotera Health Co. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XWELL, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sotera Health Co. pays -- of its earnings as a dividend. XWELL, Inc. pays out -- of its earnings as a dividend.

Sotera Health Co. quarterly revenues are $311.3M, which are larger than XWELL, Inc. quarterly revenues of $7.3M. Sotera Health Co.'s net income of $48.4M is higher than XWELL, Inc.'s net income of -$211K. Notably, Sotera Health Co.'s price-to-earnings ratio is 87.25x while XWELL, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sotera Health Co. is 4.18x versus 0.15x for XWELL, Inc.. Usually stocks with elevated PS ratios are considered overvalued.